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Sustained and safe delivery of therapeutic agents across the blood–brain barrier (BBB) is one of the major
challenges for the treatment of neurological disorders as this barrier limits the ability of most drug
molecules to reach the brain. Targeted delivery of the drugs used to treat these disorders could
potentially oﬀer a considerable reduction of the common side eﬀects of their treatment. The
preparation and characterization of carboxymethyl cellulose (CMC) coated magnetic nanoparticles
(Fe3O4@CMC) is reported as an alternative that meets the need for novel therapies capable of crossing
the BBB. In vitro assays were used to evaluate the ability of these polysaccharide coated
biocompatible, water-soluble, magnetic nanoparticles to deliver drug therapy across a model of the
BBB. As a drug model, dopamine hydrochloride loading and release proﬁles in physiological solution
were determined using UV-Vis spectroscopy. Cell viability tests in Human Lung Microvascular
Endothelial (HLMVE) cell cultures showed no signiﬁcant cell death, morphological changes or
alterations in mitochondrial function after 24 and 48 h of exposure to the nanoparticles. Evidence of
nanoparticle interactions and nanoparticle uptake by the cell membrane was obtained by electron
microscopy (SEM and TEM) analyses. Permeability through a BBB model (the transwell assay) was
evaluated to assess the ability of Fe3O4@CMC nanoparticles to be transported across a densely
packed HLMVE cell barrier. The results suggest that these nanoparticles can be useful drug transport
and release systems for the design of novel pharmaceutical agents for brain therapy.Introduction
Neurodegenerative disorders such as Parkinson's and Alz-
heimer's diseases are the leading cause of disability and the
second cause of mortality worldwide; these disorders now aﬀect
more than 250 million people globally. This number is expected
to rise substantially as current population growth and the
increase in life expectancy mean that more people will reach the
age ranges where these disorders are prevalent.1 At present, nocas, Universidad de las Ame´ricas Puebla,
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hemistry 2019cure is available for CNS disorders and they are diﬃcult to treat
pharmacologically, at best their treatment is palliative.2 Low
bioavailability, adverse reactions, and ineﬃcient targeting of
the brain are just a few of the disadvantages of the pharmaco-
logical therapies currently in use. Consequently, there is
a pressing need to develop more eﬃcient non-evasive and brain-
directed therapies for neurological disorders.
While brain-targeted drug delivery has been gaining
increasing attention, these strategies pose a signicant chal-
lenge for drug developers. Due to the very high cost of their
development and the potential for undesired side eﬀects and
long-term health risks, new pharmaceutical formulations for
the treatment of neurological disorders have the lowest
approval rate in the drug development pipeline.3 Development
of drugs for the CNS is extremely costly. Only 3–5% of the
pharmaceuticals intended for brain delivery reach the market,
as most are unable to cross the BBB in vivo.4,5 Although it is well
known that larger molecules (100%) have restricted BBB
permeability, most small molecules (>98%) are also unable to
cross the BBB. An estimated 95% of the small molecules in drugNanoscale Adv., 2019, 1, 671–685 | 671
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View Article Onlinediscovery libraries have very limited ability to permeate the BBB,
tempering their pharmacological usefulness for the treatment
of neurological disorders.4
Successful development of CNS drugs requires an under-
standing of both the pharmacological target and achieving
suﬃcient permeability across the BBB to attain eﬀective thera-
peutic concentrations in the brain. The functional complexity of
this barrier demands the development of diﬀerent strategies to
eﬀectively overcome it. One such strategy involves the design of
more eﬃcient drug delivery systems that can transport prom-
ising therapeutic and/or imaging agents over the BBB.6 There-
fore, research in the eld of nanotechnology has started to focus
on the generation of nanostructured drug delivery carriers
capable of crossing the BBB and delivering drugs to specic
sites in the brain. Nanoscale drug delivery devices can absorb
and carry drugs and then due to their ultra-tiny volume they can
pass through the smallest capillary vessels to penetrate cells
and tissue gaps. Their size allows them to avoid rapid RES
clearance, so their duration in the bloodstream is greatly
extended. The increased safety, eﬃcacy, and bioavailability of
nanoparticles (NPs) make them attractive options in the inves-
tigation of pharmacological therapies for neurological
disorders.7
Targeted delivery of these systems signicantly reduces the
required dosage, which may decrease the undesired eﬀects of
the treatment of these disorders such as adverse reactions and
toxicity.8 Although brain targeting delivery systems can enhance
the distribution of therapeutic drugs in the brain, an important
factor to consider in the design of these systems is nanoparticle
accumulation. As the treatment of chronic neurological disor-
ders oen requires long-term and frequent drug administra-
tion, nanoparticles could potentially build up in the body,
causing undesirable side eﬀects. To provide biological safety,
the materials used for these systems should be biodegradable,
compatible with the metabolic system, able to be eliminated
from the brain and have a high potential for biological and
biomimetic eﬀects. Recently, research has focused on the use of
natural materials for the fabrication of nanocarriers, as they
inherently possess many of these qualities.
Magnetite (Fe3O4) SPIONs have received widespread accep-
tance within the scientic community as their magnetic prop-
erties make them highly attractive for biomedical applications,
especially as agents for MRI and targeted drug delivery.9,10 The
biocompatibility of these particles is frequently enhanced with
organic or inorganic coatings that allow their suspension in
aqueous or organic media.11 Aer drug molecules are attached
to these delivery systems, the biodegradability, pH, ion and/or
temperature sensibility of the materials can be used to acti-
vate drug delivery at a controlled and sustained rate to the target
areas of the brain.12 An advantage of biopolymer-coated
magnetic nanoparticles is that they have shown lower toxicity
levels compared to those with bare cores. This phenomenon is
attributed primarily to the spontaneous aggregation of the bare
cores induced by the presence of plasmatic proteins and salts in
biological media. The addition of polymeric layers confers an
“anti-aggregation” barrier to the magnetic cores, as well as an
appropriate surface for functionalization.13672 | Nanoscale Adv., 2019, 1, 671–685The rst nanocarriers were coated with articial14–17 or
inorganic16,18–21 polymers. Poly(ethylene glycol) (PEG) was oen
attached to the surface of these NPs as a ‘‘stealth layer’’ to
decrease protein adsorption and to increase their concentration
in the in vivo circulation.16–18,22 However, there were a number of
drawbacks to these particles, particularly concerning their
biocompatibility and biodegradability, which may result in
adverse side eﬀects, whereas, natural polymers are proving to be
a very attractive option for coating NPs as their chemical simi-
larity to biomolecules already present in extracellular matrices
aﬀords the resulting nanomaterial high bioactivity and
biocompatibility.
The contemporary nanoparticle drug delivery eld is
studying several of these natural polymers as alternatives to
PEG. Most of this work has focused on chitosan-based mate-
rials,23–26 while comparatively little work has been done with
other polysaccharides. Polysaccharides have been reported to
reduce unspecic protein adsorption and increase plasmatic
life.27 Furthermore, the biodegradability of these materials not
only facilitates the eventual clearance of the nanocarrier but can
be exploited to trigger drug release and activation by using
certain enzymes to produce controlled degradation of the
coating.28–31 These properties, together with their ability to
interact with certain protein/cell surfaces and reduce particle
aggregation make polysaccharides very interesting materials for
the construction of brain-targeted NPs.
Carboxymethyl cellulose (CMC) is produced from the reac-
tion of cellulose (from wood pulp or cotton bers) under basic
conditions with chloroacetic acid.32 Although this biopolymer is
well known and highly versatile, successful uses of CMC for
biomedical applications of nanoparticle technologies are quite
limited. CMC can be used for the modication of magnetite
nanoparticles as the high density of carboxylate ions per chain
allow it to be physically adsorbed or conjugated on the surface
of the nanoparticles, yielding a highly stable, water-soluble
colloidal solution, and it is easy to modify with a reporter or
targeting species.33–38 Studies exploring brain delivery systems
indicate that nanoparticle surface charge has an important role
in determining cellular uptake and the interactions between
particles and cells.39 The negative charge of the CMC coating
not only has a favorable impact on the nanoparticles' colloidal
stability,39,40 it favors less plasma protein adsorption and
therefore increases the plasma circulation time of the particles
and confers other properties that make CMC a suitable coating
material for in vitro and in vivo applications in the investigation
of brain-targeted magnetic nanoparticles.41
In the past decade, enhanced properties such as adhesion of
ligands (antibodies, proteins or other systems) on the NP
surface, ligand density, and NP shape have been shown to
improve the transport of NP formulations through the BBB as
well as improving molecular recognition and controlled release
in specic targets.42–45 Although these advances have become
very popular, there are still a few important drawbacks to their
use, such as drug-release failure resulting from the high
stability of the generated bonds or reduced circulation times of
the NPs due to alteration of the physicochemical properties
when the ligands are attached.46 These drawbacks oﬀset theThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinepotential benets of active targeting as they aﬀect the
bioavailability and specic molecular recognition ability of the
NPs.47
Our group has been exploring the biomedical applications of
magnetic nanoparticles as drug carriers, MRI contrast agents and
for magnetic hyperthermia.48–53 Most recently our research has
focused on exploring alternative biocompatible polymeric coat-
ings for these nanoparticles.54,55 Here, the preparation and
characterization of CMC coated magnetite nanoparticles (Fe3-
O4@CMC) and the evaluation of their performance as drug
delivery systems for dopamine are presented. Fluorescence and
electronmicroscopy (SEM and TEM) studies were used to analyze
the cell viability of HLMVE cell cultures exposed to the magnetic
nanoparticles and their interaction with cell components. The
ability of these CMC coated SPIONs to move through a BBB
model was determined using the transwell assay. The results of
our in vitro assays suggest that these systems may be useful for
drug delivery to the brain. Furthermore, the simplicity of prepa-
ration, plentiful supply and the safety and biocompatibility of the
components of these CMC coated magnetite NPs could oﬀer
a considerable reduction in the cost of the developmental phase
of brain-targeted pharmaceuticals using these delivery systems.Experimental
Materials
Analytical grade FeCl3$6H2O, NH4OH, Na2SO3, 3-aminopropyl-
trimethoxysilane (APTMS), carboxymethyl cellulose (CMC) and
uorescein were purchased from Sigma-Aldrich; uorescent
dyes 4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes
Inc; Eugene, OR, USA) and rhodamine phalloidin (Cytoskeleton
Inc.; Denver, CO, USA) were used as received without further
purication. Water was doubly deionized, rendering conduc-
tivity in the range of 16–18 MU. Stock 2 M aqueous solutions of
FeCl3 (dissolved in HCl 2 M) and Na2SO3 were freshly prepared.
Glassware was cleaned with concentrated HCl, rinsed with
deionized water and dried before use.Synthesis of magnetite NPs (Fe3O4)
Magnetite (Fe3O4) nanoparticles were prepared based on
a previously reported method.48,56 In summary, 1.08 g of FeCl3
was dispersed in 10 mL of DI water and stirred at 500 rpm until
complete dissolution. Separately, 0.3975 g of FeCl2 was dis-
solved in 10 mL of DI water and stirred at 500 rpm until
complete dissolution. Then, the Fe(II) solution was added
rapidly to the Fe(III) solution while stirring strongly, and
immediately aerward 2.5 mL of NH4OH (30%) was added. A
black suspension formed and the recovered black solid was
washed several times with deionized water. Finally, the nano-
particles produced with this method were separated by centri-
fugation, vacuum-dried at room temperature and stored. The
nanoparticle size, as determined by TEM, was in the range of
11–17 nm. A strong tendency to agglomerate was observed in
these nanoparticles. DLS analysis of the uncoated magnetic
nanoparticles in DI water determined the average hydrody-
namic diameter to be 30 nm.This journal is © The Royal Society of Chemistry 2019Preparation of uorescein-labeled silanized magnetite NPs
(fSi–Fe3O4)
100 mg of the previously prepared magnetite was ground in an
agate mortar with anhydrous toluene (3 mL) until a ne powder
was obtained. Then, the powder was transferred to a 250 mL
round bottom ask and dispersed in 57 mL of anhydrous
toluene. A volume of 20 mL of 3-aminopropyltrimethoxysilane
(APTMS) was added to this black suspension and stirred at 60 C
for 4 hours. Finally, the magnetic precipitate was magnetically
decanted, washed twice with absolute ethanol, and then
vacuum-dried at 50 C for 30 minutes. Labeling with uorescein
was achieved following the well-known EDC/NHS coupling
protocol of adding uorescein (acid form) during silanization of
the magnetite nanoparticles in a mixture of water/DMF.57Coating with carboxymethyl cellulose (preparation of
Fe3O4@CMC and Si–Fe3O4@CMC)
Both pure Fe3O4 and Si–Fe3O4 were coated with CMC following
the same procedure. 100 mg of dried, nely ground magnetic
nanoparticles were dispersed in 10 mL of DI and sonicated for
10 min. An aqueous 0.5% solution of sodium carboxymethyl
cellulose (NaCMC) was prepared by dissolving 10 mg of NaCMC
in 10 mL of DI, mechanically stirring until complete dissolution
and then adding the NaCMC solution dropwise to the magnetic
nanoparticle suspension and stirring at 500 rpm for 10 h. Aer
this time, the material was magnetically decanted and washed
once with DI. It was then dried in a vacuum oven at 50 C for
20 min which yielded a dark brown powder. DLS analysis of
CMC coated magnetite in aqueous suspensions shows hydro-
dynamic radii in the range from 40 to 120 nm, depending on the
coating time, with zeta potential values (z) of 50 to 70 mV.Characterization
Fourier Transform Infrared (FT-IR) spectra of the nano-
structured materials were recorded using a Varian Scimitar
FTIR spectrophotometer equipped with an ATR detector and
recorded in the region of 3000–600 cm1. Dynamic light scat-
tering (DLS) and zeta potential (z) measurements were per-
formed using a Nanotrac Wave II (Microtrac) instrument,
working at 28 C in DI water as the dispersing medium, with
a red laser of 780 nm, 3 mW. The crystalline phase of the iron
oxide nanoparticles was identied by powder X-ray diﬀraction
(XRD). The patterns were collected between 20 and 70 (2q)
using a Bruker-AXS D5000 diﬀractometer on ground powders in
a quartz sample holder using the Cu Ka line source (l ¼ 1.5418
A˚); step scan ¼ 0.02; step time ¼ 0.6 s. Scanning electron
microscopy (SEM) images were obtained using a Tescan VEGA-II
microscope, with an accelerating voltage of 20 kV. SEM speci-
mens were dispersed in ethanol by ultrasonication, and a few
drops were deposited on a graphite lm adhered to an Al pin.
The size and morphology of the NP were determined by trans-
mission electron microscopy (TEM) using a JEOL JEM-120EXII
electron microscope. TEM samples were prepared by placing
one drop of a dilute suspension of magnetic nanoparticles in
water on a carbon-coated copper grid and allowing the solventNanoscale Adv., 2019, 1, 671–685 | 673
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View Article Onlineto evaporate at room temperature. The average particle size was
evaluated by measuring the largest internal dimension of 200
particles. High-resolution transmission electron microscopy
(HRTEM) analyses were performed using a JEOL Model
JEM2010 electron microscope operated at 200 kV accelerating
voltage.
Cell culture and nanoparticle internalization
HLMVE cells, obtained from the Centre for Cell Engineering at
the University of Glasgow, were grown to conuence in Dul-
becco's modied Eagle's medium (DMEM) with 50 units mL1
penicillin, 50 mg mL1 streptomycin, and supplemented with
5% fetal bovine serum (FBS), at a nal concentration of 10%. All
the media, serum, and antibiotics were provided by Life Tech-
nologies (Life Technologies, UK). Cell cultures were performed
in a 5% CO2 atmosphere at 37 C and maintained in an incu-
bator. For the experiments, the cells were seeded into 24-well
plates at an initial density of 1  104 cells per well. Treatments
were initiated three days aer plating (approximately 70%
conuence). For certain experiments (SEM and TEM analyses,
and live/dead cell detection), the cells were seeded on 13 mm
square glass coverslips placed into the wells. To analyze the
internalization of nanoparticles, HLMVE cells were grown on
coverslips and incubated for 24 h with diﬀerent concentrations
of nanoparticles (0.01, 0.1 and 1.0 mg mL1).
For SEM analysis, aer incubation, the containing medium
was removed; the cells were washed three times with PBS and
xed with 1 mL of 1.5% glutaraldehyde in cacodylate buﬀer and
2% sucrose at 4 C for 10 min. The cells were osmicated rst
with 1% osmium tetroxide, and then with 2% uranyl acetate for
5 min. Aer this, each slide was transferred into a Petri dish
containing hexamethyldisiloxane (HDMS), dried in a desiccator
and sputter-coated with a thin layer of gold in preparation for
scanning electronmicroscopy (SEM) analysis. For TEM analysis,
13 mm Thermanox coverslips for seeding cells were used in 24-
well plates; cell xation was carried out following the previously
described procedure. The samples were then dehydrated and
embedded in EPON-812 resin, then frozen in liquid nitrogen
and sectioned using an ultramicrotome. Slices were mounted
on copper grids and analyzed by transmission electron
microscopy.
Live/dead cell detection using uorescence microscopy
The cells were seeded on 13 mm square glass coverslips,
placed into 24-well plates and incubated for 24 h. Then, the
medium was replaced with fresh medium containing nano-
particles and incubated for 24 h, at 37 C and 5% CO2. Next,
the wells were washed with Ham's F-10 medium and 1 mL of
staining solution (2 mM calcein AM and 2 mM ethidium
homodimer-1) was added to each well and incubated for 1 h at
37 C. For each sample, the assay was performed in duplicate.
The cytoskeleton and cell nuclei were stained with rhodamine
phalloidin (200 mL) and DAPI (50 mL), following standard
procedures.58,59 Briey, the cells were xed in glutaraldehyde
and, permeabilized (100 mL PBS; 10.3 g sucrose; 0.292 g NaCl;
0.06 g MgCl2 (hexahydrate); 0.476 g HEPES and pH adjusted to674 | Nanoscale Adv., 2019, 1, 671–6857.2, followed by the addition of 0.5 mL Triton X). Non-specic
binding sites were blocked by incubation with PBS/1% BSA for
5 minutes at 37 C prior to incubation with rhodamine phal-
loidin for 1 hour at 37 C (Thermo Fisher Scientic, Alexa
Fluor™ 488 Phalloidin). Following washing, the cells were
further incubated with DAPI mounting medium (Vector
Laboratories). All images were viewed using an Axiophot
uorescence microscope.Evaluation of cell viability
The viability of the HLMVE cells was determined using a stan-
dard methylthiazol tetrazolium bromide (MTT) assay. Briey,
this involved incubation of the cells with unloaded or
dopamine-loaded nanoparticles in 24-well plates for 24 and
48 h, aer which MTT was added to each well (the nal
concentration of MTT was 5 mg mL1 in PBS) for 1.5 h at 37 C
and 5% CO2. Then 100 mL of DMSO was added to each dish to
dissolve the formazan crystals that formed in the cells. The
absorbance was measured with a microplate reader (Tecan
Spectra Fluor spectrophotometer) at 570 nm for each well. Cell
survival was determined by the percentage of absorption of
treated cells in comparison with that of control cells (incubated
without nanoparticles) and was calculated using the following
equation:
% Cell viability ¼ (absorbance of sample well/
absorbance of control well)  100
The results are the mean value and standard deviation (SD)
obtained from three repetitions of the experiment (n ¼ 3). The
total amount of dopamine loaded onto the nanoparticles used
for cell exposure never exceeds 0.13 mg per mg of magnetite.Transwell migration assay
Cell culture inserts (transwells) with a density of 1  105
HLVMEC cells per well were overlaid with 125 mg mL1 growth
factor-reduced Matrigel (diluted in HamF10) and placed in a 24-
well plate, at 37 C and 5% CO2, and incubated for 24 h. For
each sample, the assay was performed in duplicate. Aer
incubation, the medium was replaced with fresh medium con-
taining magnetic nanoparticles labeled with uorescein
(fSi–Fe3O4), at a concentration of 1 mg mL
1. To evaluate the
integrity of the monolayer as a BBB model the transendothelial
electrical resistance (TEER) was measured using an EVOM2
epithelial voltmeter with an STX2 electrode (World Precision
Instruments) at 12.5 Hz, as reported previously.60 These
measurements were taken during three stages of the test: before
addition of the magnetic nanoparticles, and aer 24 and 48 h of
incubation with them. Aer exposure to the magnetic nano-
particles, the culture medium in the bottom of the well was
recovered and transferred to a tube and pelleted by centrifu-
gation at 1200 rpm for 3 min. The supernatant was eliminated,
and 30 mL of the pellet was transferred to a glass slide for
analysis by uorescence microscopy.This journal is © The Royal Society of Chemistry 2019
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View Article OnlineDopamine loading and release studies
To determine the performance of the NPs as drug carrier and
release systems, dopamine hydrochloride (Aldrich) was dis-
solved in DI water and then diluted to obtain concentrations
within the range of 1 to 10 mg mL1. A UV-visible spectropho-
tometer was used to determine the absorbance of the above
concentrations at 280 nm using DI water as a blank. These
concentrations were used to plot a calibration curve. The tests
were carried out at room temperature (25 C) and pH 7.0. For
loading the nanocarrier, 10 mg of dried CMC coated magnetite
nanoparticles (Fe3O4@CMC), prepared as previously indicated,
were dispersed in 50 mL of an aqueous solution containing
dopamine (30 mg mL1) at pH 7.0, and mechanically stirred at
200 rpm for 10 h. Aer this time, the nanoparticles were
magnetically decanted and washed with ice-cold water, and
then dried for 2 h in a vacuum oven at 50 C. The amount of
dopamine loaded onto the nanoparticles was determined
spectrophotometrically (at l ¼ 280 nm) by measuring 1 mL of
aliquots at spaced intervals (0, 5, 10, 30, 60, 180, 540, and
600 min) during the incubation time. The amount of dopamine
entrapped within the nanoparticles was calculated from the
diﬀerence between the total amount of dopamine (M1) used to
prepare the nanoparticles and the amount of dopamine present
in the aqueous phase (M2). The following formula was used:
Drug loading efficiency ðDLE%Þ ¼ ðM1 M2ÞðM1Þ  100
To determine dopamine release kinetics, 10 mg of the dried
drug-loaded nanoparticles were dispersed in 50 mL of DI water
at room temperature and pH 7. The concentration of free
dopamine in the aqueous solution was determined using a UVFig. 1 Transmission (TEM) and scanning (SEM) electron microscopy imag
and (E) Fe3O4@CMC (14.05  1.70 nm); (C) and (F) Si–Fe3O4@CMC (14.
samples.
This journal is © The Royal Society of Chemistry 2019spectrophotometer under constant mechanical stirring
(200 rpm), for 4 h. 1 mL aliquots were taken at diﬀerent time
intervals (0, 5, 10, 30, 60, 180, and 240); the amount of released
dopamine was determined using the previously established
calibration curve.Results and discussion
Synthesis and characterization of magnetic nanoparticles
Nanoparticles of magnetite, Fe3O4, and silanized magnetite,
Si–Fe3O4, were synthesized as superparamagnetic carrier cores
through the chemical coprecipitation method.56,61 These
magnetic nanoparticles were coated with the polysaccharide
carboxymethyl cellulose (CMC) by an electrostatic adsorption
method.62 Silanization of the magnetite nanoparticles was
tested to ascertain if it improved the stability of the NPs as well
as the immobilization of CMC on the nanoparticle surface. No
signicative diﬀerences were found between the non-silanized
and silanized CMC-coated nanoparticles. The hydrodynamic
radii were similar in both cases (around 110.0  10.0 nm), and
the aqueous suspensions were stable for several days at room
temperature, which agrees with their highly negative zeta
potential values. The morphology and size distribution of the
nanomaterials were characterized by SEM and TEM. Fig. 1
shows selected representative scanning (SEM) and transmission
electron microscopy (TEM) images of the diﬀerent magnetic
nanoparticles in this work (Fe3O4, Fe3O4@CMC, and Si–Fe3-
O4@CMC nanoparticles); the particles are mostly spherical and
show a narrow size distribution, with average sizes of 19.90 nm
 3.06 nm (Fe3O4), 14.05  1.70 nm (Fe3O4@CMC) and 14.96 
4.16 nm (Si–Fe3O4@CMC). Smaller nanoparticle average sizes
were obtained when the nanoparticles were coated with CMC,es of magnetic nanoparticles: (A) and (D) Fe3O4 (14.38  3.06 nm); (B)
96  4.16 nm). Insets are HRTEM micrographs for the corresponding
Nanoscale Adv., 2019, 1, 671–685 | 675
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View Article Onlinewhich may be the result of reduced agglomeration of these NPs
in solution. The average sizes of these magnetic nanoparticles
are in the range required for superparamagnetism, as well as for
biomedical applications.63Fig. 2 XRD pattern showing the characteristic magnetite/maghemite
diﬀraction peaks of the prepared nanoparticles: (A) Fe3O4; (B)
Fe3O4@CMC; (C) Si–Fe3O4@CMC.
Fig. 3 Fourier transform infrared spectra of the prepared magnetic nano
676 | Nanoscale Adv., 2019, 1, 671–685The nanoparticle's crystalline phase was identied by X-ray
diﬀraction (XRD) (Fig. 2). The XRD pattern (Fig. 2) showed six
characteristic peaks [(220), (311), (400), (422), (511), and (440)],
which are consistent with the main phases of the magnetite and
maghemite diﬀraction peaks, and no traces of other iron oxide
phases were found. The silanization or CMC coating of
magnetite nanoparticles did not inuence the crystalline pha-
ses. Fourier transform infrared spectra of the prepared nano-
particles (Fig. 3A) show that the characteristic band for the Fe–O
stretching was located near 590 cm1. New vibrational bands
appear at frequencies between 800 and 1100 cm1 due to the
presence of aminopropylsilane on the surface (Fig. 3B) and
between 1000 and 1700 cm1 associated with C–O and C–C
bonds due to the presence of CMC on the nanoparticle surface
(Fig. 3D). The polysaccharide molecules adsorbed on the
nanoparticle surface stabilize the particles in aqueous suspen-
sion. The surface charge of the CMC coated magnetite NPs was
in the range of 56 to 69 mV, as determined by zeta potential
(z) measurements.
Nanoparticle internalization and cytotoxicity
HLMVE cells were exposed to 0.1 mg mL1 of magnetic nano-
particles in the cell culture medium for 24 h. Analysis by
confocal uorescence microscopy of cells stained with calcein
AM and ethidium homodimer-1 showed isolated live cells
(green), negligible aggregation of the nanoparticles and no
evidence of dead cells (red) aer 24 h of incubation (Fig. 4a–c).
The analysis of HLMVE cells stained with rhodamine phalloidin
and DAPI (Fig. 4d–f) showed isolated cells, with no morpho-
logical abnormalities of the cytoskeleton and well-formedparticles: (A) Fe3O4; (B) Si–Fe3O4; (C) pure CMC; (D) Si–Fe3O4@CMC.
This journal is © The Royal Society of Chemistry 2019
Fig. 4 Fluorescence microscopy micrographs of HLMVE cells, after 24 h of exposure to 0.1 mg mL1 of magnetic nanoparticles: cells stained
with calcein-AM and ethidium homodimer-1: (A) Si–Fe3O4@CMC, 10; (B) Fe3O4@CMC, 10; (C) Fe3O4, 10; and rhodamine phalloidin and
DAPI stained cells, (D) Fe3O4, 10; (E) Fe3O4@CMC, 10; (F) Si–Fe3O4@CMC, 10.
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View Article Onlinenuclei aer 24 h of exposure to the nanoparticles. These results
indicate that the nanoparticles have no signicant eﬀect on the
cell morphology or development, suggesting that they are not
toxic to them. The degree of cell survival (cell viability) was
evaluated by the standard methyl thiazol tetrazolium bromide
(MTT) assay. The analysis of cytotoxicity aer incubation of
HLMVE cells with 0.01, 0.1 and 1.0 mg mL1 of nanoparticles
showed that the viability of cell cultures is not signicantly
aﬀected or modied by the presence of the nanoparticles aer
24 and 48 h of treatment (90–100% viability in relation to the
control sample, as shown in Fig. 5a). No negative eﬀect on cell
viability was observed when the same systems (Fe3O4, Fe3-
O4@CMC, and Si–Fe3O4@CMC) were loaded with dopamine
(Fig. 5b).
Both SEM and TEM analyses were used to examine the
interaction of the nanoparticles with the cell membrane.
Fig. 6a–c show overlapped nanoparticle aggregates and HLMVE
cells. Although it is not clear whether the nanoparticles are on
the cell membrane or inside, almost no nanoparticles were
found “outside” the cells, and all cells presented external
morphological changes (pseudopod-like) that may be related to
an endocytosis or pinocytosis process during the interaction
with the magnetic nanoparticles. In addition, a large number of
actin brils (worm-like structures in Fig. 6d and f) wereThis journal is © The Royal Society of Chemistry 2019observed in the intracellular medium, which suggests that a cell
internalization process took place. Considering that cells start
assimilating nutrients and other substances from the culture
medium during the rst hour, the observation of large aggre-
gates near the cell nucleus suggests that nanoparticles are
internalized, although it is not clear what the uptake mecha-
nism is. TEM analysis was performed to determine whether the
nanoparticle aggregates were inside or outside the cells. Fig. 6g
and h show slices of HMLVE cells that had been exposed to the
loaded and unloaded magnetic nanoparticles. Large aggregates
are visible inside one vesicle. No diﬀerences were observed in
the aggregates of silanized or unsilanized magnetic nano-
particles coated with CMC. These results suggest that the
nanoparticles, rst, aggregate outside the cell membrane and
then they are internalized into the cells through endocytosis or
pinocytosis, accumulating inside specialized vesicles. The
intracellular pattern of nanoparticle distribution in the cyto-
plasm, outside the cell nucleus, may indicate that they are
stored inside endosomes, which are acidic compartments used
for nutrient storage and digestion, suggesting that the mecha-
nism of internalization is endocytosis. In previous studies, we
have observed similar processes of nanoparticle uptake in
diﬀerent cell lines.48,55 The CMC coating increased the stability
of both the silanized and unsilanized magnetic nanoparticles,Nanoscale Adv., 2019, 1, 671–685 | 677
Fig. 5 Cell viability for HLMVE cells exposed to 0.01, 0.1 and 1.0 mg mL1 doses of magnetic nanoparticles, with and without dopamine (+D)
loading, after 24 h: (a) Fe3O4; (b) Fe3O4@CMC; (c) Si–Fe3O4@CMC; and after 48 h: (d) Fe3O4; (e) Fe3O4@CMC; (f) Si–Fe3O4@CMC.
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View Article Onlinethereby improving their chances of being internalized by the
HMLVE cells.Transwell inset assay
An in vitromodel consisting of a monolyaer of HLMVE cells was
used for preliminary evaluation of the BBB permeability of the
CMC coated magnetic nanoparticles. For this study, a bi-
compartmentalized transwell was employed in which HLMVE
cells were grown to conuence in the upper chamber. HLMVE
cells were seeded onto transwell inserts on 24-well plates (n¼ 2)
containing Ham's F-10 medium at 37 C and 5% CO2 (1  105
cells per well). The cells were incubated for 24 h, aer this time
themedium was replaced with fresh medium containing 0.1 mg
mL1 of uorescein-labeled Fe3O4@CMC or Si–Fe3O4@CMC
nanoparticles.678 | Nanoscale Adv., 2019, 1, 671–685The integrity of the grown BBB model was evaluated using
TEER measurements at the onset and during the experiments,
and these were compared to the control (non-cultured wells).
Before the addition of uorescein-labeled magnetic nano-
particles, the TEER value for the non-cultured wells (control)
was on average 219  7 U cm2. 24 h aer the addition of
magnetic nanoparticles the TEER values of Fe3O4@CMC and Si–
Fe3O4@CMC were on average 212 5 U cm2 and 195 5 U cm2,
respectively, while aer 48 h they were on average 197 
13 U cm2 and 185  12 U cm2. The resulting TEER value of
200 U cm2 is considered consistent with the formation of an
intact BBB. Aliquots were taken from the lower chamber aer 24
and 48 h and analyzed with a uorescence microscope.
Fluorescein labeling of the magnetic nanoparticles was used for
monitoring their transmigration from the upper to lower
chamber in the transwell inset through the BBB model. InThis journal is © The Royal Society of Chemistry 2019
Fig. 6 SEM and TEMmicrographs of HLMVEC after 24 h of exposure to 0.1 mgmL1 of nanoparticles; SEM: (A) Fe3O4, 1000; (B) Fe3O4, 6000;
(C) Fe3O4@CMC, 1000; (D) Fe3O4@CMC, 6000; (E) Si–Fe3O4@CMC, 1000; (F) Si–Fe3O4@CMC, 6000; TEM: (G) Fe3O4; (H) Fe3O4@CMC; (I)
Si–Fe3O4@CMC.
Fig. 7 Fluorescence microscopy images in Ham's F-10 medium recovered from the lower chamber of transwell inserts with a monolayer of
HLMV endothelial cells after 24 and 48 h of exposure to ﬂuorescein-labeled magnetic nanoparticles: (A) Si–Fe3O4@CMC after 24 h; (B)
Si–Fe3O4@CMC after 48 h; (C) Fe3O4@CMC after 24 h; (D) Fe3O4@CMC after 48 h.
This journal is © The Royal Society of Chemistry 2019 Nanoscale Adv., 2019, 1, 671–685 | 679
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View Article OnlineFig. 7, the presence of uorescent nanoparticles is evident in the
recovered medium of the lower chamber for both systems
(uorescein labeled Fe3O4@CMC and Si–Fe3O4@CMC), even
aer just 24 h. This result indicates that the uorescein labeled,
CMC coated magnetic nanoparticles can cross through the
densely packed barrier of HLMV endothelial cells used as a BBB
model. Silanized magnetite nanoparticles coated with CMC had
a higher transmigration rate than those that were not silanized,
and they had a lower propensity for aggregation in the medium.
The values of TEER were near the standard 200 U cm2 at the
beginning of the experimental period and remained close to
this value aer 24 and 48 h, suggesting that exposure to the
uorescein labeled, CMC coated magnetic nanoparticles did
not compromise the integrity of the BBB model. The results
obtained from this BBB model are in agreement with those
previously obtained by Thomsen and co-workers, who studied
the uptake and transport of SPIONs through an in vitro BBB
model made of human brain capillary endothelial cells
(HBCEC).64Fig. 8 Dopamine proﬁles for (A) drug LE% and (B) drug release
(mg L1) in aqueous solution at room temperature and pH 7.In vitro drug loading and release of the magnetic
nanoparticles
The Fe3O4@CMC system was selected for the evaluation of
dopamine loading and release. For this evaluation, magnetic
nanoparticles were loaded with dopamine. Up to 0.13 mg of
dopamine was loaded in the nanocarrier per mg of magnetite.
This amount was calculated by considering the total amount of
dopamine available in the solution and the amount of magne-
tite dispersed in it. Fig. 6 shows the drug loading eﬃciency
percentage (LE%) for Fe3O4@CMC over a period of 10 h and the
dopamine release prole over 4 h at room temperature and pH
7.0. A drug LE% of 84.6% was estimated (Fig. 8a), which is
comparable with those of other drug-loaded drug nanocarriers
reported in the literature.65 These results indicate that the CMC
coated Fe3O4 nanoparticles load up to 70% of the available drug
during the rst hour and then, they can release up to 81.6% of
the loaded dopamine when re-dispersed in DI water. Fig. 8b
shows the cumulative amount of released dopamine from the
magnetic nanocarrier versus time. Dopamine release occurred
rapidly during the rst hour (nearly 40%); this was likely to have
been the dopamine adsorbed on the surface of the carrier. The
remaining dopamine released at a slower rate during the next
few hours, which can be associated with the release of the
dopamine in the polymeric coating, reaching almost an
invariant concentration in solution aer 4 hours. The
sustained-release pattern suggests that this system may be
a good candidate for controlled drug delivery and release,
although the release prole in physiological solution still needs
to be determined.
Dopamine release kinetics were analyzed using various
mathematical models (zero-order, Qt ¼ Q0 + K0t; rst order,
ln Qt ¼ ln Q0 + Ket and Higuchi, Qt ¼ Q0 + Kht1/2). Considering
the R2 values, the calculated zero-order (R2 ¼ 0.926) and rst-
order (R2 ¼ 0.718) models were not appropriate to describe
the drug release kinetics. The release kinetics appeared to be
square root time-dependent, as in the Higuchi model (R2 ¼680 | Nanoscale Adv., 2019, 1, 671–6850.992), suggesting that diﬀusion plays an important role in the
release of the drug.
CMC-coated magnetic particles appear to have signicant
potential for in vivo magnetic eld assisted drug delivery. As
magnetic ferrouids are capable of interaction with external
magnetic elds, these colloidal dispersions are ideal for
magnetic targeting drug delivery applications. The use of
a magnetic ferrite core gives Fe3O4@CMC NPs the potential to
be actively delivered, localized, and targeted to the desired
region, tissue or type of cell. Aer the administration of these
SPIONs, an external magnetic eld may be applied to the region
of interest, drawing the NPs to that specic site.66 The null
residual magnetization of SPIONs aer removal of the external
magnetic eld allows the NPs to disperse and avoids magneti-
cally induced agglomeration in veins or arteries and also avoids
phagocytosis while the circulation half-time is increased.46,67
Stereo-specic manipulation of magnetic elds to guide nano-
particles to a precise location in the brain is currently being
studied.68 Nevertheless, there are still many challenges to
overcome before considering clinical applications of this tech-
nology for brain targeting in humans. Studies using the appli-
cation of static, strong Nd–Fe-B magnets to certain anatomic
regions showed large concentrations of SPIONs in tissues close
to the permanent magnet, with a decrease in concentration asThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinethe distance from the magnet increases, clearly indicating that
the NPmigration in the body can be controlled by using external
magnetic elds.69–71However, studies have shown that it is more
diﬃcult to target sites located farther from the magnetic source
and specic targeting has been more successful in small animal
models than in larger animals or humans. Technological
advances such as the development of devices capable of
generating “on/oﬀ” magnetic elds within the brain would
optimize the practical application of magnetically targeted drug
delivery systems for the treatment of neurological disorders.
The surface charge of CMC coated magnetite NPs is depen-
dent on the pH and the amount of CMC and may be tailored to
improve their BBB permeability. Although studies have shown
that NPs with high positive charge are immediately toxic to the
BBB,72 in some cases NPs with moderate (1 to15mV) or high
(15 to 45 mV) negative zeta (z) potentials and even moderate
(up to 15 mV) or higher positive z-potentials73–76 have been able
to cross the BBB and deliver drugs to the brain.77,78 This may be
due to the greater cellular uptake prole of positively charged
NPs in brain microvessel endothelial cells compared with
negatively charged IONPs of similar size.79,80 Experiments using
magnetic eld assisted permeability show increased uptake for
nanoparticles with a greater negative charge, suggesting that
negatively charged NPs are likely to follow a paracellular route,
which makes them more suitable for magnetic assisted drug
targeting.81 An in vitro study of carboxymethyl dextran-coated
NPs concludes that the uptake of most negatively charged
particles seems to occur via non-specic interactions.39
The characteristics of these versatile NPs make them apt for
multi-modal functions. In addition to their potential for drug
delivery to the brain, they can serve simultaneously as magnetic
resonance imaging contrast agents. Furthermore, radiocontrast
agents may be attached to these delivery systems, which would
facilitate better imaging and diagnosis of neurodegenerative
disorders. The negative z-potentials of CMC/Fe3O4 NPs make
these particles apt for another interesting application for brain-
targeted magnetic nanoparticles. As recently reported by Dante
et al., the NP surface charge is key for the modulation of neuronal
electrical activity.82 Their ndings regarding selective NP–neuron
interactions open up the possibility for novel applications of NPs
in neuroscience, specically for the design of NPs capable of
neuronal subtype-specic targeting. This research suggests that
negatively charged NPs could be used in long-term imaging as
markers of active neurons, which would enable visualization of
the aberrant increased neuronal activity of neurological disor-
ders. In addition, the increase in neuronal activity produced by
these NPs could be used to increase the activity of inhibitory
neurons with reduced excitability, which is a hallmark of the
severe forms of epilepsy.83 These NPsmay eventually be utilized to
modulate the balance between excitation and inhibition in the
brain, which is a signicant factor in most neurological diseases.
Conclusions
Superparamagnetic nanoparticles coated with a layer of the
biocompatible polysaccharide CMC were prepared and fully
characterized. Cell viability assays, as well as a completeThis journal is © The Royal Society of Chemistry 2019analysis of their interaction with the cell membrane, cell
internalization and ability to pass through a model of the blood-
brain barrier (BBB), were performed in cell cultures. No indi-
cation of toxicity was found, and our results indicated that the
nanoparticles accumulated in endosomes. Clear evidence of
crossing through a barrier of densely packed endothelial cells
was observed; these results indicate that CMC coated magnetic
nanoparticles may show great potential as drug delivery systems
for neurological treatments. Further testing is required for the
continued development of this drug delivery system.
In summary, the physicochemical properties of CMC/Fe3O4
NPs can be tailored for use in diﬀerent applications and are
very attractive for brain-targeted magnetic nanoparticle
research. Aer the attachment of drug molecules to these
delivery systems, the neutral to negative surface charge of the
CMC coating may facilitate BBB crossing.82,84 The biodegrad-
ability of the coating of the nanoparticles allows the drug to be
delivered at a controlled and sustained rate to the target site in
the brain. In addition to the already proven advantages of
paramagnetic NPs for drug delivery, the ferrite cores allow
magnetic eld targeting that could favor both permeability of
the BBB and specicity of the drug release site.64,85 The CMC
coating creates a hydrophilic surface that avoids agglomera-
tion, increases nanoparticle dispersion in physiological solu-
tion and extends bioavailability; it also provides an appropriate
surface for functionalization with targeting moieties to trigger
drug release or an enzymatic stimulus, which would allow for
even more precise targeting of specic cells. Targeted delivery
of these systems would signicantly reduce the required
dosage of the therapeutic agent, which may decrease the
undesired eﬀects of the treatment of neurological disorders
such as adverse reactions and toxicity. Furthermore, the
simplicity of preparation, plentiful supply and the safety and
biocompatibility of the components of these CMC coated
magnetite NPs could oﬀer a considerable reduction in the cost
of the developmental phase of brain-targeted pharmaceuticals
using these delivery systems.Author contributions
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